3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
17
Lymphoma
16
Multiple Myeloma
13
Neoplasm Metastasis
10
Leukemia, Myeloid, Acute
10
Melanoma
9
Lung Neoplasms
9
Prostatic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Squamous Cell Carcinoma of Head and Neck
6
Lymphoma, Non-Hodgkin
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Neuroblastoma
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Lymphoma, Follicular
4
Burkitt Lymphoma
4
Wilms Tumor
3
Small Cell Lung Carcinoma
3
Sarcoma, Kaposi
3
Sarcoma
3
Rhabdoid Tumor
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Precancerous Conditions
3
Ovarian Neoplasms
3
Osteosarcoma
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Myeloproliferative Disorders
3
Myelodysplastic Syndromes
3
Medulloblastoma
3
Interventions
aldesleukin
15
Cyclophosphamide
15
fludarabine phosphate
12
fludarabine
11
Interleukin-2
10
Nivolumab
6
Ipilimumab
6
Temozolomide
5
pembrolizumab
3
Fluorouracil
3
trametinib
2
sonidegib
2
dabrafenib
2
binimetinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Sodium Chloride
2
Sirolimus
2
Radiotherapy
2
Radiation
2
Peptides
2
HhAntag691
2
Gefitinib
2
Dacarbazine
2
Cyclosporine
2
Cetuximab
2
Capecitabine
2
veliparib
1
varlilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Skin Neoplasms
×
Biopsy
×
Clear all
NCT00715793
2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2
Completed
39 enrolled
12 charts